Skip to main content
SpringerLink
Log in

Intraperitoneal Delivery Systems

  • Chapter
  • First Online:
Exploring Drug Delivery to the Peritoneum

  • 48 Accesses

Abstract

Intraperitoneal delivery (IPD) has been in practice since the early twentieth century and has since been employed for treating various ailments from ascites to cancer. Given the nature of IPD, this modality of drug delivery has received a lot of interest and attention specifically in the area of treating tumors in the colon, ovary, and abdominal region. This chapter attempts to provide an overview of key principles of IPD with respect to concentrations of drug that can be delivered, toxicity, efficacy, and important criteria for IPD. It also discusses different methods of IPD including conventional IPD drug delivery techniques as well as continuous infusion and implantable IP systems. Finally, this chapter discusses the advantages and challenges for different types of drug molecules and drug delivery mechanisms for delivery via the IPD route.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BNP:

Bioadhesive Nanoparticles

HIPEC:

Hyperthermic Intraperitoneal Chemotherapy

IP:

Intraperitoneal

IPD:

Intraperitoneal Delivery

IPDD:

Intraperitoneal Drug Delivery

IPDDS:

Implantable Intraperitoneal Drug Delivery Systems

MW:

Molecular Weight

NIH:

National Institute of Health

PILLSID:

PILL-refilled Implanted System for Intraperitoneal Delivery

SE:

Standard Error

References

  1. Kalra A, Wehrle CJ, Tuma F. Anatomy, abdomen and pelvis, peritoneum. Treasure Island: StatPearls [Internet]. StatPearls Publishing; 2023 Jan; 2022.

    Google Scholar 

  2. Andres I-R, et al. The peritoneum: beyond the tissue – a review. Front Physiol. 2018;9(738):1–12.

    Google Scholar 

  3. Granger HJ. Role of the interstitial matrix and lymphatic pump in regulation of transcapillary fluid balance. Microvasc Res. 1979;18(2):209–16.

    Article  CAS  PubMed  Google Scholar 

  4. Fraser PA, et al. Microvascular pressures and filtration coefficients in the cat mesentery. J Physiol. 1978;283:436–56.

    Article  Google Scholar 

  5. Esperanca MJ, Collins DL. Peritoneal dialysis efficiency in relation to body weight. J Pediatr Surg. 1966;1(2):162–9.

    Article  Google Scholar 

  6. Alfonso MA, et al. Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas. Surg Radiol Anat. 2009;31(5):369–77.

    Article  Google Scholar 

  7. Williams R, White H. The greater omentum: its applicability to cancer surgery and cancer therapy. Curr Probl Surg. 1986;23(11):789–865.

    Article  CAS  PubMed  Google Scholar 

  8. Surbone A, Myers C. Principles and practice of intraperitoneal therapy. J Antimicrob Chemother. 1988;40:14–25.

    CAS  Google Scholar 

  9. Flessner MF, et al. Exchange of macromolecules between peritoneal cavity and plasma. Am J Phys. 1985;248(1):15–25.

    Google Scholar 

  10. Mactier RA, Khanna R. Absorption of fluid and solutes from the peritoneal cavity. Theoretic and therapeutic implications and applications. ASAIO Trans. 1989;35(2):122–31.

    Article  CAS  PubMed  Google Scholar 

  11. George RS, et al. Pneumococcal vaccines: the impact of conjugate vaccines. ASM Press; 2008.

    Google Scholar 

  12. Charlie G, et al. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2016;36:143–51.

    Article  Google Scholar 

  13. Esquivel J, et al. Techniques of delivering hyperthermic intraperitoneal chemotherapy. In: Intraperitoneal cancer therapy. Humana Press; 2007. p. 163–77.

    Chapter  Google Scholar 

  14. Markman M. Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin. Ther Clin Risk Manag. 2009;5:161–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sugarbaker P, Anthony Stuart O. Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases. Eur J Surg Oncol. 2021;47(1):108–14.

    Article  PubMed  Google Scholar 

  16. Dedrick RL, Flessner MF, Collins JM, Schultz JS. Is the peritoneum a membrane? Am Soc Artif Organs. 1982;5:1–8.

    Google Scholar 

  17. Flessner MF, et al. A distributed model of peritoneal–plasma transport: theoretical considerations. Am J Physiol. 1984;246(4):597–607.

    Google Scholar 

  18. Flessner MF, et al. A distributed model of peritoneal–plasma transport: tissue concentration gradients. Am J Physiol. 1985;248(3):425–35.

    Google Scholar 

  19. Ze L, et al. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010;6(10):1625–41.

    Article  Google Scholar 

  20. Yang D, et al. Improved i.p. drug delivery with bioadhesive nanoparticles. Appl Biol Sci. 2016;113(41):11453–8.

    Google Scholar 

  21. Nantional Cancer Institute staff. Intraperitoneal chemotherapy in advanced ovarian cancer improves survival, but is underused. Nantional Cancer Institute, 4 September 2015. [Online]. Available: https://www.cancer.gov/news-events/cancer-currents-blog/2015/ip-chemo. Accessed 12 June 2023.

  22. C. f. D. C. a. Prevention. Antineoplastic (chemotherapy) drugs – reproductive health. CDC, 1 May 2023. [Online]. Available: https://www.cdc.gov/niosh/topics/repro/antineoplastic.html. Accessed 12 June 2023.

  23. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet. 2003;4:277–83.

    Article  CAS  Google Scholar 

  24. de Bree E, et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47–62.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yamamoto M, et al. Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: beyond EPR effect. J Control Release. 2022;352:328–37.

    Article  CAS  PubMed  Google Scholar 

  26. Wang Y, et al. 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer. 2010;10(402):1–8.

    Google Scholar 

  27. Goldberg M, et al. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022;13(4829):1–14.

    Google Scholar 

  28. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol. 2006;24(28):4531–3.

    Article  PubMed  Google Scholar 

  29. Gourley C, et al. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2016;36(May 2016):143–51.

    Article  Google Scholar 

  30. Dagasan Cetin G, et al. Intraperitoneal instillation versus wound infiltration for postoperative pain relief after cesarean delivery: a prospective, randomized, double-blind, placebo-controlled trial. J Obstet Gynaecol. 2023;49(1):209–19.

    Article  CAS  Google Scholar 

  31. Nivedita J, Ajay KJ. Intraperitoneal instillation of local anesthetics: is this a suitable alternative for postcesarean pain relief without toxicity profiling? Anasth Analg. 2017;125(1):352.

    Article  Google Scholar 

  32. Mahalanabis D, et al. Intraperitoneal fluid therapy in cholera and non-cholera diarrhoea: with special emphasis on the treatment of infants and children. Bull World Health Organ. 1970;42(6):837–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Rubin J, et al. Intraperitoneal feeding. ASIAO Trans. 1988;34(2):125–30.

    Article  CAS  Google Scholar 

  34. Akoh JA. Peritoneal dialysis associated infections: an update on diagnosis and management. World J Nephrol. 2012;1(4):106–22.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Turner PV, et al. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Fleten KG, et al. Alginate microsphere encapsulation of drug-loaded nanoparticles: a novel strategy for intraperitoneal drug delivery. Marine Drugs. 2022;20:744–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dagbert F, et al. Intraperitoneal distribution of alginate microcapsules in mice. Mod Chemother. 2014;3(1):42444.

    Article  Google Scholar 

  38. Yamaguchi K, et al. Intraperitoneal administration of a cisplatin-loaded nanogel through a hybrid system containing an alginic acid-based nanogel and an in situ cross-linkable hydrogel for peritoneal dissemination of ovarian cancer. Mol Pharm. 2021;18(11):4090–8.

    Article  CAS  PubMed  Google Scholar 

  39. Emoto S, et al. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci. 2012;103(7):1304–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Pozza G, et al. Long-term continuous intraperitoneal insulin treatment in brittle diabetes. Br Med J Clin Res Ed. 1983;286:255–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Iacovacci V, et al. A fully implantable device for intraperitoneal drug delivery refilled by ingestible capsules. Sci Robot. 2021;6(57):eabh3328.

    Article  PubMed  Google Scholar 

  42. Dedrick RL, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(8):1–11.

    CAS  PubMed  Google Scholar 

  43. Fujiwara K, et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17(1):1–20.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang Y, et al. mPEG-PDLLA micelles potentiate docetaxel for intraperitoneal chemotherapy in ovarian cancer peritoneal metastasis. Front Pharmacol. 2022;13:861938.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Li J, et al. Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo. Cancer Sci. 2018;109(6):1958–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zahedi P, et al. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. J Control Release. 2012;158(3):379–85.

    Article  CAS  PubMed  Google Scholar 

  47. Van De Sande L, et al. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis – a phase I first-in-human study. Pleura Peritoneum. 2018;3(2):2018–0112.

    Google Scholar 

  48. Astrid H, et al. Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models. Nanomedicine. 2023;48:102656.

    Article  Google Scholar 

  49. Hagiwara A, et al. Pharmacologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodents. Cancer. 1991;71(3):844–50.

    Article  Google Scholar 

  50. De Clercq K, et al. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer. Sci Rep Nat Res. 2019;9:14881.

    Article  Google Scholar 

  51. U.S. National Library of Medicine, Clinicaltrials.gov, National Institute of Health, 15 June 2023. [Online]. Available: https://clinicaltrials.gov/ct2/results?cond=&term=intraperitoneal&cntry=&state=&city=&dist=. Accessed 15 Jun 2023.

Download references

Author information

Authors and Affiliations

  1. Aurobindo Pharmaceuticals USA Inc., Dayton, NJ, USA

    Rohit Ghan

  2. Kite Pharma (A Gilead Company), Los Angeles, CA, USA

    Sonali Shaligram

  3. Calidi Biotherapeutics Inc., San Diego, CA, USA

    Amish Patel

Authors
  1. Rohit Ghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonali Shaligram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amish Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Freie Universität Berlin, Berlin, Germany

    Ranjita Shegokar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ghan, R., Shaligram, S., Patel, A. (2023). Intraperitoneal Delivery Systems. In: Shegokar, R. (eds) Exploring Drug Delivery to the Peritoneum. Springer, Cham. https://doi.org/10.1007/978-3-031-31694-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-31694-4_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-31693-7

  • Online ISBN: 978-3-031-31694-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation